Original Research Paper



Oral Pathology

AN IMMUNOHISTOCHEMICAL STUDY OF E-CADHERIN, VIMENTIN
AND KI-67 EXPRESSION IN RESPECT TO CLINICOPATHOLOGICAL
PROFILE OF ORAL SQUAMOUS CELL CARCINOMA IN A TERTIARY CARE
CENTRE

Dr. Tabassum Iqbal MD Pathology (Senior Resident) Osmania medical college.

Dr Naga Kalyani Pathuri

MD Pathology (Associate Professor) Osmania medicak college.

Dr Vani Padmaja

MD Pathology (Professor and HOD) Osmania medical college.

INTRODUCTION:- According to WHO, Oral cancer is one of the three most prevalent cancers in Asia, among which India accounts for approximately one third. Immunological markers E-cadherin, Vimentin and Ki-67 plays a major role in determining invasiveness, metastasis and prognosis of Oral Squamous Cell Carcinoma. AIM:- To study the expression of immunological markers E-cadherin, Vimentin and Ki-67 in Oral Squamous Cell Carcinoma and evaluate their expression concerning clinicopathological profile. METHODS:-It is a hospital-based cross-sectional study of 60 cases of Oral Squamous Cell Carcinoma done for two years. Expression of immunological markers E-cadherin, Vimentin and Ki-67 were evaluated and correlated with its pathology. RESULTS:- Majority of the patients with Oral Carcinoma belonged to the 51 – 60 years age group with male predominance(2.3:1). 45% had on Tongue, 22% on the buccal mucosa, 12% on Hard palate, 8% on Lips, 5% on Soft palate and Uvula,3% on Anterior pillar and Retromolar trigone and 2% on Floor of mouth. E-cadherin was positive in 72% with 38% strong positivity. Vimentin was positive in 33% with 20% strong positivity. Ki-67 expression was high in 67% of the cases. Lymph node metastasis showing 13% E-cadherin positivity, 22% Vimentin positive, 30% Ki-67 positive. CONCLUSION:-OSCC cell proliferation research must be further extended as it can be helpful to forecast survival rates for a deeper understanding of protein expression and the interaction between biomarker and therapeutic aspects of these patients.

KEYWORDS: E-cadherin, Vimentin, Ki-67, OSCC

INTRODUCTION

According to the World health organization (2018), one of the three most prevalent cancers in Asia and the Pacific is oral cancer (Carcinoma of the lips and mouth) with India accounting for approximately one-third of the total burden and oral cancer is the sixth most prevalent cancer worldwide. Tobacco, alcohol and usage of the areca nut are all known to cause oral cancer. An increasing number of young persons in North America and Europe are developing oral malignancies due to Human papillomavirus infection. India is home to roughly 77,000 new cases and 52,000 fatalities a year, which is about one-fourth of the worldwide incidences. Oral squamous cell carcinoma (OSCC) is a major cause of oral cancer, accounting for 84-97 percent.

The epithelial to mesenchymal transition (EMT), which is common in Oral squamous cell carcinoma, involves the loss of epithelial morphology and the development of mesenchymal features. Many epithelial markers including E-cadherin, desmoplakin, cytokeratin and claudins, are downregulated in cells prior to EMT. E-cadherin is an intracellular domain that interacts with its cytoplasmic binding partner catenin to connect it to the actin cytoskeleton. Vimentin is a marker for cells that are in transition from epithelial to mesenchymal features. Ki-67 is a proliferation marker for cells. Ki-67 overexpression is also utilized to determine if a patient is at high risk of malignant transformation and for grading Oral squamous cell carcinoma. In this research, immunohistochemistry was used to assess the expression of epithelial E-cadherin, Vimentin and Ki-67 in Oral squamous cell carcinoma, as well as its grading concerning invasion, metastasis and cellular proliferation.

AIMSAND OBJECTIVES:-

- To evaluate Immunohistochemical expression of E-cadherin, Vimentin and Ki-67 in Oral Squamous Cell Carcinoma.
- To assess the role of these markers to determine invasion, metastasis and cellular proliferation.

METHODOLOGY:-

This study is a hospital based cross-sectional study done on 60 cases of Oral Squamous Cell Carcinoma done for a period of 2 years from (November 2018- November 2020). Sampling method:-All the diagnosed cases presented to the hospital were included. Inclusion criteria:- positive biopsy specimens of Oral Squamous Cell Carcinoma with adequate tissue for analysis. Exclusion criteria:- Squamous Cell Carcinoma with inadequate tumour tissue and Patients not willing to participate. Method:-The oral biopsy specimens were preserved in a 10% formaldehyde solution. Immunohistochemistry was used to

evaluate the expression of E- cadherin, and histological diagnosis was made on haematoxylin and eosin-stained sections. Ethics: ethical clearance was obtained from the institution, and informed consent was obtained from participants. Analysis:-The data was collected, coded and entered in Microsoft excel, and the excel sheet was exported to IBM SPSS software (21 edition trial version) for analysis. The results are presented in the form of frequencies and percentages. The Chisquare test was applied wherever necessary. A P-value of less than 0.05 was considered significant.

RESULTS:-

Table no.1 shows, a majority (33%) of the study population belonged to the age group of 51–60yrs and the Male: Female ratio was 2.3:1. Out of 60 cases, 45% of the cases had Carcinoma Tongue. 22% of cases had Carcinoma on Buccal mucosa. 12% of the cases had Carcinoma on the Hard palate. 8% of the cases had Carcinoma on lip.

Table No.1 Distribution Of Age Gender, Site Of Cancer Tumor Grade And Lymph Node Metastasis Among Study Population

VARIABLES FREQUENCY PERCENTAGE AGE 31 - 40 9 15.00% 41 - 50 11 18.33% 51 - 60 20 33.33% 61 - 70 12 20.00% >70 8 13.33% GENDER Male 42 70% Female 18 30% Female 18 30% Bucal mucosa 13 21.66% Tongue 27 45.00% Floor of mouth 1 1.66% Retromolar trigone 2 3.33% Hard palate 7 11.66% Soft palate, Uvula 3 5.00% Anterior pillar 2 3.33% Tumour Grade Well Differentiated 42 70% Moderately Differentiated 42 70% Moderately Differentiated 4 7% Lymph node Present 22 36.66% Metastasis Absent 38 63.33% <th></th> <th></th> <th></th> <th></th>					
A1 - 50	VARIABLES	FREQUENCY	PERCENTAGE		
S11 - 60 20 33.33% 61 - 70 12 20.00% >70 8 13.33% 61 - 70 8 13.33% 61 - 70 8 13.33% 61 - 70 8 13.33% 62 70% Female 18 30% 63 64 64 64 64 64 64	AGE	31 - 40	9	15.00%	
Company		41 - 50	11	18.33%	
STO S 13.33%		51 - 60	20	33.33%	
GENDER Male 42 70% Female 18 30% SITE Lip 5 8.33% Buccal mucosa 13 21.66% Tongue 27 45.00% Floor of mouth 1 1.66% Retromolar trigone 2 3.33% Hard palate 7 11.66% Soft palate, Uvula 3 5.00% Anterior pillar 2 3.33% Tumour Grade Well Differentiated 42 70% Moderately Differentiated 42 70% Moderately Differentiated 4 7% Lymph node Present 22 36.66%		61 - 70	12	20.00%	
Female		>70	8	13.33%	
SITE Lip 5 8.33% Buccal mucosa 13 21.66% Tongue 27 45.00% Floor of mouth 1 1.66% Retromolar trigone 2 3.33% Hard palate 7 11.66% Soft palate, Uvula 3 5.00% Anterior pillar 2 3.33% Tumour Grade Well Differentiated 42 70% Moderately Differentiated 14 23% Poorly Differentiated 4 7% Lymph node Present 22 36.66%	GENDER	Male	42	70%	
Buccal mucosa 13 21.66% Tongue 27 45.00% Floor of mouth 1 1.66% Retromolar trigone 2 3.33% Hard palate 7 11.66% Soft palate, Uvula 3 5.00% Anterior pillar 2 3.33% Tumour Grade Well Differentiated 42 70% Moderately Differentiated 14 23% Poorly Differentiated 4 7% Lymph node Present 22 36.66%		Female	18	30%	
Tongue 27 45.00% Floor of mouth 1 1.66% Retromolar trigone 2 3.33% Hard palate 7 11.66% Soft palate, Uvula 3 5.00% Anterior pillar 2 3.33% Tumour Grade Well Differentiated 42 70% Moderately Differentiated 14 23% Poorly Differentiated 4 7% Lymph node Present 22 36.66%	SITE	Lip	5	8.33%	
Floor of mouth 1 1.66% Retromolar trigone 2 3.33% Hard palate 7 11.66% Soft palate, Uvula 3 5.00% Anterior pillar 2 3.33% Tumour Grade Well Differentiated 42 70% Moderately Differentiated 14 23% Poorly Differentiated 4 7% Lymph node Present 22 36.66%		Buccal mucosa	13	21.66%	
Retromolar trigone 2 3.33% Hard palate 7 11.66% Soft palate, Uvula 3 5.00% Anterior pillar 2 3.33% Tumour Grade Well Differentiated 42 70% Moderately Differentiated 14 23% Poorly Differentiated 4 7% Lymph node Present 22 36.66%		Tongue	27	45.00%	
Hard palate 7 11.66% Soft palate, Uvula 3 5.00% Anterior pillar 2 3.33% Tumour Grade Well Differentiated 42 70% Moderately Differentiated 14 23% Poorly Differentiated 4 7% Lymph node Present 22 36.66%		Floor of mouth	1	1.66%	
Soft palate, Uvula 3 5.00% Anterior pillar 2 3.33% Tumour Grade Well Differentiated 42 70% Moderately Differentiated 14 23% Poorly Differentiated 4 7% Lymph node Present 22 36.66%		Retromolar trigone	2	3.33%	
Anterior pillar 2 3.33% Tumour Grade Well Differentiated 42 70% Moderately Differentiated 14 23% Poorly Differentiated 4 7% Lymph node Present 22 36.66%		Hard palate	7	11.66%	
Tumour Grade Well Differentiated 42 70% Moderately Differentiated 14 23% Poorly Differentiated 4 7% Lymph node Present 22 36.66%		Soft palate, Uvula	3	5.00%	
Moderately Differentiated 14 23% Poorly Differentiated 4 7% Lymph node Present 22 36.66%		Anterior pillar	2	3.33%	
Poorly Differentiated 4 7% Lymph node Present 22 36.66%	Tumour Grade	Well Differentiated	42	70%	
Lymph node Present 22 36.66%		Moderately Differentiated	14	23%	
		Poorly Differentiated	4	7%	
Metastasis Absent 38 63.33%		Present	22	36.66%	
	Metastasis	Absent	38	63.33%	

Well Differentiated Tumour was found in 70% of the cases. Moderately Differentiated Tumour was found in 23% of the cases. Poorly Differentiated Tumour was found in 7% of the cases. Out of 60 Cases, lymph node metastasis was present in 22 (37%) of the cases and

in 38 (63%) of the cases, lymph node metastasis was not found.

Table No.2 Distribution Of-cadherin And Vimentin Expression In

Kelation with fullor Graue							
TUMOUR GRADE	E-CADHERIN		VIMENTIN				
	POSITIVE	NEGATIVE	POSITIVE	NEGATIVE			
WELL- DIFFERENTIATED	35(56.66%)	7(13.33%)	8(13.33%)	34(56.66%)			
MODERATELY	7(13.33%)	7(13.33%)	9(15%)	5(8.33%)			
DIFFERENTIATED							
POORLY	1(1.66%)	3(5%)	3(5%)	1(1.66%)			
DIFFERENTIATED							
P-VALUE	0.005	0.01					

Table no.2 shows, E-cadherin was positive in 57% of the Well Differentiated and 13% of the Moderately Differentiated Tumour cases. Vimentin was positive in 13% of the Well Differentiated and 15% of the Moderately Differentiated Tumour cases. The difference between the groups was found to be statistically significant (p-value < 0.05).

Table No.3: distribution Of Ki-67 Expression In Relation With **Tumor Grade**

TUMOUR GRADE	Ki-67		
	LOW	BORDERLINE	HIGH
WELL-DIFFERENTIATED	4(6.6%)	17(28.3%)	21(35%)
MODERATELY	1(1.6%)	2(3.3%)	11(18.3%)
DIFFERENTIATED			
POORLY DIFFERENTIATED	2(3.3%)	1(1.66%)	1(1.6%)
TOTAL	7	20	33
P-VALUE	0.04		

Table no.3 shows Ki-67 expression was high in 35% of Differentiated Tumours, borderline in 28.3% of the Well Differentiated Tumours, and low in 6.6% of the Well Differentiated Tumours. Ki-67 expression was high in 1.6% of the Poorly Differentiated Tumours, borderline in 1.66% of the Poorly Differentiated Tumours and low in 3.3% of the Poorly Differentiated Tumours.

FIGURE 1-4. A case of Well Differentiated Carcinoma showing strong positivity of E-cadherin, Vimentin negative and Ki-67 positive only in basal layer of epithelium.




Fig 1:H&E(10X)




Fig 2: E-cadherin(10X)-Strong positive






Fig 3: Vimentin(40X) - Negative Fig 4: Ki-67(10X) - Focal positive only in basal layer

Figure 5-8: A case of Moderately Differentiated Squamous Cell Carcinoma, showing weak positivity of E-cadherin, weak positivity of Vimentin and high Ki-67 positivity.





Fig 5: H&E(10X)

Fig 6: E-cadherin(10x) weak positive







Fig 7: Vimentin(40x) weak positive Fig 8: Ki-67(10X) high proliferative index

Figure 9-12:-A case of Poorly Differentiated Carcinoma showing negative E-cadherin, positive Vimentin, high Ki-67 positivity







Fig9:H&E(10X)

Fig10:E-cadherin(40X)-negative






Fig11: Vimentin(40x) positive

Fig12: Ki-67(40x) high proliferative index

DISCUSSION:-

In the present study, male predominance was observed. Our study results were identical to CL. Margaritescu et al.10 Patel M et al.11, Marwah et al.study12 also reported similar results with males and females contributing 75 per cent and 25 per cent, respectively. In this present study, the majority of the patients with Oral Carcinoma belonged to the age group of 51 - 60 yrs with 33%. In a study done by Jing ping et al.13 compared with age group and E-cadherin also Vimentin positivity and observed that the majority of patients over 50 years of age were E-cadherin and Vimentin positive. The p values measured were not important for either age group and marker positivity correlation.

In the present study, a majority of cases had Carcinoma Tongue followed by Carcinoma of Buccal mucosa. This finding was also seen in similar studies done by Subha Bhat et al.14 and CA Fischer et al.15.

In this study, the majority of cases were Well-Differentiated, followed

by Moderately-Differentiated followed by Poorly-Differentiated histological form. Similar findings were seen in CL. Margaritescu et al.10, but another study by Marwah et al.12 showed more Moderately Differentiated histological form.

In the present study, more than half the cases had lymph node metastasis; among them, only 22% of the cases were Vimentin positive and 13% Ecadherin positive. Similar findings were seen Jing ping et al. 13. Thus, the lymph node metastasis statistical correlation shows increased Vimentin expression and diminished E-cadherin expression. In this study, a correlation was made with the advancing age group and the expression of E-cadherin and Vimentin. The positivity of E-cadherin was found to be more in Well and Moderately Differentiated, the expression of Ecadherin was decreased or absent in Poorly Differentiated Tumours, and the expression of E-cadherin was negative or lost in those tumours with invasive nature and positive for lymph node metastasis. Vimentin was statistically significant in Poorly Differentiated Tumours with increased positivity and lymph node metastasis.

Ki-67 is a predictor for cell proliferation in multiple tumours. The activity of Ki-67 tumour proliferation was established in connection with tumour aggression, which is determined by the tumour grade and stage. Many studies have represented these relations and established Ki-67 as a forecasting factor. The results of this study support that Ki-67 is a widely articulated independent predictor for OSCC. In consideration of the large variety of tumours, more studies need to improve spatial associations between Ki-67 and OSCC.

CONCLUSION:-

This present study demonstrated the relationship of E-Cadherin, Vimentin and Ki-67 in forecasting the possibility of invasion and metastasis and prognosis of the patients. 66.6% of the cases showed a high proliferation index which is regarded as a poor prognostic indicator and increased chances of recurrence. Ki-67 is an established prognostic, predictive and survival protein marker. Its expression is higher in Moderately Differentiated and Poorly Differentiated Squamous Cell Carcinoma. So this relationship of E-cadherin, Vimentin and Ki-67 helps in forecasting the possibility of invasion, metastases and prognosis of an individual. In conclusion, OSCC cell proliferation research must be further extended as it can be helpful to forecast survival rates for a deeper understanding of protein expression and the interaction between biomarker and therapeutic aspects of these patients.

Abbreviations:- OSCC- Oral squamous cell carcinoma, E-Cadherin epithelial cadherin.

Acknowledgment:-None.

Declarations:- Funding: None, Competing interests: None declared.

- Ferlay J EM, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Published 2018. Accessed 14 September, 2020.
- Borse V, Konwar AN, Buragohain P. Oral cancer diagnosis and perspectives in India. Sensors International. 2020;1:100046. Epub 2020 Sep 24.

 Mehrtash H, Duncan K, Parascandola M, et al. Defining a global research and policy
- agenda for betel quid and areca nut. Lancet Oncol. 2017;18(12):e767-e775.

 Mehanna H, Beech T, Nicholson T, et al. prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer-systematic review and meta-analysis of trends by time and region. Head Neck. 2013;35(5):747-755.
- Ajay P., Ashwinirani S., Nayak A., Suragimath G., Kamala K., Sande A., Naik R. Oral ncer prevalence in Western population of Maharashtra, India, for a period of 5 years. J. Oral Res. Rev. 2018;10:11.
- Kalluri, Raghu, and Robert A Weinberg. "The basics of epithelial-mesenchymal transition." The Journal of clinical investigation, 2009, vol. 119,6: 1420-8. 6.
- Mège RM, Ishiyama N. Integration of Cadherin Adhesion and Cytoskeleton at Adherens
- Junctions. Cold Spring Harb Perspect Biol. 2017 May 1;9(5):a028738.

 Mendez, Melissa G et al. "Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition." FASEB journal: official publication of the Federation of American Societies for Experimental Biology vol. 24,6 (2010): 1838-51.
- 9. Takkem A. Barakat C. Zakaraja S. Zaid K. Naimeh J. Avoub M. Seirawan MY. Ki-67 Prognostic Value in Different Histological Grades of Oral Epithelial Dysplasia and Oral
- Squamous Cell Carcinoma. Asian Pac J Cancer Prev. 2018 Nov 29;19(11):3279-3286. Cl Margaritescu, Cristiana Simionescu et al. Endoglin(CD105) and microvessel density in oral squamous cell carcinoma. Romanian journal of Morphology and Embryology. 2008; 49(3): p. 321-326.
- AN, Patel M M and Pandya. Relationship of oral cancer with age, sex, site distribution
- and habits. Indian J Pathol Microbiol. 2004; 47(2): p.195-197.

 Marwah N, Parmar P, Parshad S, Yadav T, Gupta S, Sen R. Morphological assessment of Micro Vessel Density in Head and Neck Squamous Cell Carcinoma using Immuno marker CD105 and its correlation with clinicopathological parameters. Clinical Cancer Investigation Journal. 2016; 5(4): p.309-14.
- Jing ping, Detao et al expression of e cad and vim in oral SCC ,ijclin exp path
- Shubha P Bhat, Ramesh Naik C N, G K Swetadri, Hilda D'souza, Jayaprakash C S, Vadishabhat. Clinicopathological spectrum of Malignancies of Oral cavity and

- oropharynx-our experience in a Referral Hospital. World article in ear, nose and throat archives. 2016;2(1):OA3
- Fischer, C A et al. "p16 expression in oropharyngeal cancer: its impact on staging and prognosis compared with the conventional clinical staging parameters." Annals of oncology : official journal of the European Society for Medical Oncology 2010,vol. 21,10:1961-1966.
- Zhang, J., Zhang, W., Gao, P. et al. Expression of E-cadherin in oral squamous cell carcinoma is associated with clinical prognosis. Chin. J. Clin. Oncol. 2006,vol 3, p181-184